<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.1011412</article-id><article-id pub-id-type="publisher-id">ACM-38819</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20201100000_41244638.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  肝癌的过继性细胞免疫治疗应用的进展研究
  Research Progress of Adoptive Cellular Immunotherapy for the Treatment of Hepatocellular Carcinoma
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>蓁臻</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>爱绮</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>龚</surname><given-names>建平</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>重庆市忠县人民医院，重庆</addr-line></aff><aff id="aff3"><addr-line>重庆医科大学附属第二医院，重庆</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>04</day><month>11</month><year>2020</year></pub-date><volume>10</volume><issue>11</issue><fpage>2710</fpage><lpage>2715</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    肝细胞肝癌是世界上最常见的恶性肿瘤之一，主要的治疗方式包括手术切除、射频消融、经导管动脉化疗栓塞术(Transarterial chemoembolization, TACE)、放化疗等。目前还有各种相关抗肿瘤的免疫治疗，广泛研究的免疫细胞主要有：树突状细胞(DC)、细胞因子诱导杀伤细胞(CIK)、共培养免疫细胞(DC-CIK)、嵌合抗原受体T细胞(CAR-T)等。治疗措施的选择取决于肿瘤阶段、大小及其肿瘤微环境状态。本文就过继性免疫细胞疗法在肝癌临床治疗中的应用作一综述。
    Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world. The main treatment methods include surgical resection, radiofrequency ablation, TACE, chemoradiotherapy and so on. At present, there are a variety of anti-tumor immunotherapies. The immune cells extensively studied include dendritic cells (DC), cytokine induced killer cells (CIK), co-cultured immune cells (DC-CIK), chimeric antigen receptor T cells (CAR-T), etc. The choice of treatment depends on the tumor stage, size, and tumor microenvironmental status. This article reviews the application of adoptive immune cell therapy in the clinical treatment of liver cancer. 
  
 
</p></abstract><kwd-group><kwd>肝癌，免疫细胞，过继治疗，综述, Hepatocellular Carcinoma</kwd><kwd> Immune Cells</kwd><kwd> Adoptive Therapy</kwd><kwd> Review</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>肝细胞肝癌是世界上最常见的恶性肿瘤之一，主要的治疗方式包括手术切除、射频消融、经导管动脉化疗栓塞术(Transarterial chemoembolization, TACE)、放化疗等。目前还有各种相关抗肿瘤的免疫治疗，广泛研究的免疫细胞主要有：树突状细胞(DC)、细胞因子诱导杀伤细胞(CIK)、共培养免疫细胞(DC-CIK)、嵌合抗原受体T细胞(CAR-T)等。治疗措施的选择取决于肿瘤阶段、大小及其肿瘤微环境状态。本文就过继性免疫细胞疗法在肝癌临床治疗中的应用作一综述。</p></sec><sec id="s2"><title>关键词</title><p>肝癌，免疫细胞，过继治疗，综述</p></sec><sec id="s3"><title>Research Progress of Adoptive Cellular Immunotherapy for the Treatment of Hepatocellular Carcinoma<sup> </sup></title><p>Zhenzhen Chen<sup>1</sup>, Aiqi Zhang<sup>2</sup>, Jianping Gong<sup>2</sup></p><p><sup>1</sup>Zhongxian Hospital, People’s Hospital of Chongqing, Chongqing</p><p><sup>2</sup>The Second Affiliated Hospital of Chongqing Medical University, Chongqing</p><p><img src="//html.hanspub.org/file/46-1571644x4_hanspub.png" /></p><p>Received: Nov. 2<sup>nd</sup>, 2020; accepted: Nov. 19<sup>th</sup>, 2020; published: Nov. 26<sup>th</sup>, 2020</p><p><img src="//html.hanspub.org/file/46-1571644x5_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Hepatocellular carcinoma (HCC) is one of the most common malignant tumors in the world. The main treatment methods include surgical resection, radiofrequency ablation, TACE, chemoradiotherapy and so on. At present, there are a variety of anti-tumor immunotherapies. The immune cells extensively studied include dendritic cells (DC), cytokine induced killer cells (CIK), co-cultured immune cells (DC-CIK), chimeric antigen receptor T cells (CAR-T), etc. The choice of treatment depends on the tumor stage, size, and tumor microenvironmental status. This article reviews the application of adoptive immune cell therapy in the clinical treatment of liver cancer.</p><p>Keywords:Hepatocellular Carcinoma, Immune Cells, Adoptive Therapy, Review</p><disp-formula id="hanspub.38819-formula42"><graphic xlink:href="//html.hanspub.org/file/46-1571644x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/46-1571644x7_hanspub.png" /> <img src="//html.hanspub.org/file/46-1571644x8_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>原发性肝细胞癌(HCC)起病隐匿，恶性程度高，易于复发和转移。在全球范围内，HCC是最常见的恶性肿瘤。早期肝癌术后需要辅助治疗，包括:TACE、射频治疗等。虽然这些治疗方法可以有效地治愈局部病灶，但不能解决复发和转移的问题。对于晚期癌症患者仍然没有有效的治疗方法。HCC的发生、发展、转移和复发与免疫系统损伤密切相关。随着肿瘤抗原的形成，免疫系统中T淋巴细胞的特异性细胞毒性活动不能被激活，从而阻止机体对肿瘤抗原产生继发免疫应答。免疫治疗通过激活有效的抗肿瘤免疫反应，使免疫系统识别肿瘤特异性蛋白并产生免疫反应，从而激活特异性免疫清除肿瘤 [<xref ref-type="bibr" rid="hanspub.38819-ref1">1</xref>]。过继性免疫细胞治疗 [<xref ref-type="bibr" rid="hanspub.38819-ref2">2</xref>] 的抗肿瘤作用，可通过注入自体细胞或异基因特异性或非特异性免疫细胞来纠正细胞免疫功能低下的状态，减少病人的复发率，延长无进展生存时间和总生存时间。</p></sec><sec id="s6"><title>2. 过继性免疫治疗分类</title><sec id="s6_1"><title>2.1. 树突状细胞(Dendritic Cells, DC)</title><p>DC具有自身的免疫刺激作用，是免疫应答的活化、调节维持的中心。正常情况下，DC用于捕获抗原，并通过主要组织相容性复合体(MHC)分子将抗原呈现给幼稚T细胞，使T细胞成熟 [<xref ref-type="bibr" rid="hanspub.38819-ref3">3</xref>] 并发挥抗肿瘤活性。另一方面，DC可以分泌针对初始细胞的趋化性细胞因子(CCKs)并促进其聚集和增殖，维持效应T细胞在肿瘤部位的长期存在 [<xref ref-type="bibr" rid="hanspub.38819-ref4">4</xref>]。DC可以刺激B淋巴细胞的生长和分化，增强抗肿瘤抗体介导的免疫应答 [<xref ref-type="bibr" rid="hanspub.38819-ref5">5</xref>]，抵抗肿瘤细胞的免疫逃逸。HCC患者DCs常表现为异常分化和成熟障碍，导致无法激活抗原特异性T细胞应答。HCC患者局部淋巴结内DCs比例减少，功能性DCs明显减少 [<xref ref-type="bibr" rid="hanspub.38819-ref6">6</xref>]。因此，功能性DCs的体外导入对肝癌的积极免疫治疗具有重要意义。临床上，EI Ansary [<xref ref-type="bibr" rid="hanspub.38819-ref7">7</xref>] 评估了自体DC疫苗和其他支持性治疗对晚期HCC的安全性和有效性。将患者分为两组，一组(15例)接种自体DC细胞疫苗，另一组仅接受一般支持治疗。结果表明：DC疫苗上调患者CD8+T细胞和IFN-γ水平，延长患者总生存率。目前DC疫苗的临床效果有限，其中导致其临床应用较少的因素之一是缺乏诱导有效的抗肿瘤免疫应答的标准 DC疫苗生产程序 [<xref ref-type="bibr" rid="hanspub.38819-ref8">8</xref>]。目前，利用抗体与DC表面的受体(如toll样受体)结合，诱导DC成熟可以产生抗肿瘤免疫 [<xref ref-type="bibr" rid="hanspub.38819-ref9">9</xref>]。然而，DC疫苗并不直接刺激CD8+T细胞，相反，它促进了抗原向内源性APC的转移，从而激活CD8+T细胞。今后的研究应更多关注DC疫苗对CD8+T细胞的直接刺激，使机体产生特异性抗肿瘤免疫应答 [<xref ref-type="bibr" rid="hanspub.38819-ref10">10</xref>]，这可能是肝癌免疫治疗的关键。今后的研究仍需重点设计DC疫苗制备策略，进一步提高免疫治疗的敏感性和特异性，最大限度地发挥其免疫诱导和调节潜能。</p></sec><sec id="s6_2"><title>2.2. 细胞因子诱导杀伤细胞(Cytokine-Induced Killer Cells, CIK)</title><p>本模板可直接用CIK细胞是一种异质免疫细胞群，由多种细胞因子(CD3Mc Ab、IL-2、IFN-spider、IL-1等)体外刺激人外周血单核细胞产生的异质性细胞，主要作用是CD3+ [<xref ref-type="bibr" rid="hanspub.38819-ref11">11</xref>] 和CD56+ [<xref ref-type="bibr" rid="hanspub.38819-ref12">12</xref>] 的表达。它也被称为NK-like T淋巴细胞，因为它具有很强的抗肿瘤活性和NK的非MHC(主要组织相容性复合体)的限制 [<xref ref-type="bibr" rid="hanspub.38819-ref13">13</xref>]，可以直接识别和杀伤肿瘤细胞。由于其抗肿瘤活性强、抗肿瘤谱广、对骨髓或造血细胞无明显毒副作用，已成为肿瘤过继免疫治疗的研究热点。CIK主要通过以下机制杀伤肿瘤细胞：1) 体外培养时CIK细胞分泌各种细胞因子，如IFN-γ，TNF-α，Il-2并激活巨噬细胞，NK细胞和CD8+T细胞的细胞毒性活动。CIK细胞对肿瘤细胞有直接的抑制作用，也可促进间接杀伤作用 [<xref ref-type="bibr" rid="hanspub.38819-ref14">14</xref>]；2) CIK通过粘附分子LFA-1/cam-1途径与肿瘤细胞上的抗原结合，促进MHC-I或II分子的表达，以增强肿瘤抗原的递呈、活化、识别和对肿瘤细胞的直接细胞毒性；3) CIK细胞通过诱导survivin和defender against cell death 1 (DAD1)等凋亡基因的表达，促进抗肿瘤基因的表达，诱导细胞毒性，促进肿瘤细胞凋亡 [<xref ref-type="bibr" rid="hanspub.38819-ref15">15</xref>]；4) CIK细胞可以表达Fas L (II跨膜糖蛋白)，与肿瘤细胞膜上表达的Fas (I跨膜糖蛋白)结合，导致细胞凋亡。CIK在体外通过PBMCs扩增产生。序贯加入重组人IFNγ，抗-CD3单克隆抗体和重组人IL2是细胞培养获得CIK细胞所必需的。在14~21天的孵育后，可以获得CIK细胞并将其输入患者体内，发挥抗肿瘤作用。补充的细胞因子和抗体不仅可以提高PBMC在体外的活化和增殖能力，还可以增加CIK细胞对肿瘤细胞的溶细胞活性。</p><p>一项对410例HCC患者的回顾性临床研究显示 [<xref ref-type="bibr" rid="hanspub.38819-ref16">16</xref>]，CIK辅助治疗组的总体生存率高于单纯手术治疗组，并提示CIK辅助治疗组中有较大病灶的患者的总生存率大幅高于单纯手术治疗组。Schmeel等人总结了CIK治疗HCC的 24个I期临床结果和21个II期临床试验。他们的结果表明，与对照组相比，接受CIK细胞治疗的HCC患者的总体生存期延长了40%以上 [<xref ref-type="bibr" rid="hanspub.38819-ref17">17</xref>]。然而，还需要建立一个完善的预后系统和对大规模临床试验的额外指导，以帮助临床医生确定HCC患者是否能从辅助CIK细胞免疫治疗中获益40。Yu R [<xref ref-type="bibr" rid="hanspub.38819-ref18">18</xref>] 等人分析CIK免疫治疗作为HCC辅助治疗的有效性和安全性。结果显示，CIK治疗组的生存率显著高于对照组((HR = 0.594, 95% CI = 0.501~0.703, P, 0.001))，说明CIK细胞免疫治疗可以广泛应用于提高肝癌患者的生存率的及降低复发率。Lee的研究 [<xref ref-type="bibr" rid="hanspub.38819-ref19">19</xref>] 确定反复注射CIK细胞后CIK细胞治疗是否继续有效。162名肝癌患者(免疫治疗组89例和对照组73例)在最后一名患者随机分组后进行了60个月的延长随访。在中位期68.5个月的随访期间，免疫治疗组的复发或死亡风险继续显著降低。5年后，免疫治疗组和对照组无复发生存率(RFS)福分别为44.8%，33.1%。与对照组相比，免疫治疗组的全因死亡风险也较低。辅助CIK细胞免疫治疗后，HCC患者的RFS和总生存期(OS)均有显著改善，持续时间超过5年，且无增加。CIK的抗肿瘤作用依赖于肿瘤微环境中活跃的免疫细胞的富集，需要在一定时间内维持其生物活性。健康对照组的CIK生长增殖率明显高于肿瘤组，说明健康个体的CIK具有较强的抗肿瘤活性。在生理状态下，CD3+和CD56+ T淋巴细胞占正常外周血的(1%~5%)，远不能满足临床治疗的需要。布莱诺等 [<xref ref-type="bibr" rid="hanspub.38819-ref20">20</xref>] 收集的来自患者和健康对照组的PBMCs，由抗胸腺细胞球蛋白共刺激(TG, IFN-γ and IL-2)，结果表明高剂量TG组诱导的CIK扩增效率明显提高。增加了各种NK细胞的活性和抑制受体，分泌大量的IL-12p40蛋白，裂解后杀死靶细胞。这说明TG作为一种新的CIK辅助诱导剂，可以促进CIK的活化和增殖。提高CIK细胞培养效率，提高CIK细胞活性，增强CIK细胞的肿瘤杀伤活性已成为当前研究的重要领域。</p></sec><sec id="s6_3"><title>2.3. 共培养免疫细胞(Dendritic Cell/ Cytokine-Induced Killer Cells, DC-CIK)</title><p>CIK细胞通过释放大量炎症因子和诱导细胞凋亡，快速有效地杀伤肿瘤细胞。DC-CIK细胞可体外培养增殖，获得单个核细胞，直接经静脉进入血液循环后即可识别并杀死肿瘤细胞。研究表明，改良DC和CIK细胞共培养可以增加抗肿瘤活性，一方面可以促进DC成熟，分泌大量细胞因子，诱导Th1免疫应答清除肿瘤细胞。同时，CIK细胞组的调节性T细胞减少，CIK细胞的杀伤活性进一步增强。Chen等人 [<xref ref-type="bibr" rid="hanspub.38819-ref21">21</xref>] 在一项31例DC-CIK治疗后患者的临床研究中发现，HCC患者的总体疾病控制率为64.5%。7例患者出现寒战、高热等不同程度的毒性反应，但均在可控范围内，说明DC-CIK细胞免疫治疗HCC是比较安全有效的。虽然手术是治疗HCC最直接的方法，但术后肝内的小病灶一直是肝癌复发和转移的重要危险因素。DC-CIK联合治疗可明显延长患者术后生存时间，提高患者生活质量。在临床回顾性研究，张 [<xref ref-type="bibr" rid="hanspub.38819-ref22">22</xref>] 发现，经导管动脉化疗栓塞术的治疗效果(TACE)结合DC-CIK对肝癌细胞免疫治疗明显优于单独TACE治疗，以及PD-L1的表达水平可以作为疗效的关键因素。除了在HCC治疗中的应用外，DC-CIK治疗在慢性乙型肝炎(CHB)的治疗中也得到了应用。Ma YJ [<xref ref-type="bibr" rid="hanspub.38819-ref23">23</xref>] 等人将HBsAg诱导的DC-CIK细胞注射到慢性乙型肝炎患者体内，发现33例患者中有21例的HBV复制被抑制，这说明HBsAg可抑制HBV病毒复制，激活DC-CIK细胞后可降低HCC发生的风险。此外，联合应用还可敏感作用于耐多药肿瘤细胞，增强免疫同时抗肿瘤。</p></sec><sec id="s6_4"><title>2.4. 嵌合抗原受体T细胞(Chimeric Antigen Receptor T Cells, CAR-T)</title><p>CAR-T免疫治疗是利用基因工程技术修饰T细胞，使其发挥抗肿瘤作用的一种特殊的治疗手段 [<xref ref-type="bibr" rid="hanspub.38819-ref24">24</xref>]。嵌合抗原受体(CAR)设计和整合到T细胞中形成CAR-T细胞，贯穿整个免疫治疗过程，是这种治疗方式最关键的技术。目前应用最广泛的CAR结构包括单链抗体胞外结构域、胞外铰链结构域、跨膜结构域和胞内结构域，这些结构域可以识别和结合特定抗原。与传统T细胞的TCR结构相比，CAR结构不依赖于主要组织相容性复合体(MHC)抗原的呈递，避免了MHC分子限制，解决了由于MHC分子表达下调导致肿瘤的免疫逃逸问题 [<xref ref-type="bibr" rid="hanspub.38819-ref25">25</xref>] 除了一些普通的CAR-T治疗在研究阶段，最广泛使用的CAR-T免疫治疗是一种个性化的细胞治疗方法，每个患者必须完成体外培养的自体免疫细胞再灌注治疗。CAR-T细胞必须被运输和渗透到肿瘤部位，以发挥其细胞溶解作用。静脉注射是将CAR-T细胞重新引入恶性血液病患者体内的有效途径。然而，由于区域脏器的血液分布相对有限，这种方法在HCC治疗中是不可行的。CAR-T细胞通过静脉流注入了血液在血管很少渗透HCC病灶甚至可能严重损害肺部和其他正常的器官。此外，由肝纤维化和肝硬化发展而来的HCC肿瘤具有高度的纤维化，难以渗透。这些特征使CAR-T细胞进入肿瘤部位变得复杂；同样，患者对其他免疫治疗(如检查点抑制剂)反应较弱 [<xref ref-type="bibr" rid="hanspub.38819-ref26">26</xref>]。大量的研究集中在引入趋化因子到CAR结构中以克服渗透障碍。其他一些策略也可用于促进CAR-T细胞向肿瘤组织的浸润。经导管动脉化疗栓塞术(TACE)是一种影像诊断与临床治疗相结合的介入治疗方法，是肝癌非手术治疗的首选方法。鉴于静脉注射对肝细胞癌治疗的不良影响，临床医生可以以介入方式注入CAR-T细胞。该方法可以提高杀伤细胞向肿瘤组织浸润的效率，大幅降低全身性副反应。然而，TACE细胞再灌注剂量的确定仍然存在问题，取决于肝肿瘤的大小和数量以及个体差异。因此，确定最有效和最安全的输入剂量可能是今后必须处理的一项困难任务。</p><p>目前CAR-T细胞治疗在血液系统恶性肿瘤的临床治疗中取得了巨大的进展。然而，致命的作用也发生在临床实践中。在典型的CAR-T细胞治疗中，一名肝转移患者出现严重的呼衰竭，最终死亡。CAR-T细胞治疗的毒性作用包括细胞因子释放综合征(CRS)、噬血淋巴组织细胞增生综合症和CAR-T细胞相关脑病综合征。减少不良事件和最大限度地提高CAR-T细胞的临床效率至关重要，因为副作用无法完全避免。</p></sec></sec><sec id="s7"><title>3. 研究展望</title><p>在肝癌的诸多治疗方法中，过继性免疫治疗比传统的治疗策略显示出独特的优势，与抗体或其他靶向药物相比，是一种有活性的治疗方法，可以在体内激活和增殖，具有强烈持久的抗肿瘤作用。过继性免疫治疗的基本原理是提高抑制肿瘤细胞生长和存活的细胞的数量和质量，打破肿瘤细胞的免疫耐受。过继性免疫治疗可以在如下方面进行进一步改进：1) 过继性免疫治疗被认为是一种高度个性化的癌症治疗，因为大多数效应细胞都是从患者身上获得的。目前过继细胞群制备没有标准，刺激因子的选择和时间的确定是重要问题；2) 肝癌的治疗方法虽然多种多样，但各有局限，建议采用综合治疗方法，而不是单一的治疗方法，不同形式的组合可能协同增强免疫治疗的有效性；3) 在关注过继性免疫治疗疗效的同时，注意解决相关并发症及不良事件发生的问题。综上所述，如何在肝癌过继性免疫细胞治疗中进一步提高疗效，减少治疗副作用仍需进一步研究。如何使免疫细胞特异性地识别肝癌细胞表面的特异性肿瘤抗原，并特异性地攻击肝癌细胞，将是肝癌免疫细胞治疗的研究方向。</p></sec><sec id="s8"><title>文章引用</title><p>陈蓁臻,张爱绮,龚建平. 肝癌的过继性细胞免疫治疗应用的进展研究Research Progress of Adoptive Cellular Immunotherapy for the Treatment of Hepatocellular Carcinoma[J]. 临床医学进展, 2020, 10(11): 2710-2715. https://doi.org/10.12677/ACM.2020.1011412</p></sec><sec id="s9"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.38819-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Sia, D., Jiao, Y., Martinez-Quetglas, I., et al. (2017) Identification of an Immune-Specific Class of Hepatocellular Carcinoma, Based on Molecular Features. Gastroenterology, 153, 812-826. &lt;br&gt;https://doi.org/10.1053/j.gastro.2017.06.007</mixed-citation></ref><ref id="hanspub.38819-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Dzhandzhugazyan, K.N., Guldberg, P. and Kirkin, A.F. (2018) Adoptive T Cell Cancer Therapy. Nature Materials, 17, 475-477. &lt;br&gt;https://doi.org/10.1038/s41563-018-0094-5</mixed-citation></ref><ref id="hanspub.38819-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Gammaitoni, L., Giraudo, L., Macagno, M., et al. (2017) Cytokine-Induced Killer Cells Kill Chemo-Surviving Melanoma Cancer Stem Cells. Clinical Cancer Research, 23, 2277-2288. &lt;br&gt;https://doi.org/10.1158/1078-0432.CCR-16-1524</mixed-citation></ref><ref id="hanspub.38819-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Cornel, A.M., van Til, N.P., Boelens, J.J., et al. (2018) Strategies to Genetically Modulate Dendritic Cells to Potentiate Anti-Tumor Responses in Hematologic Malignancies. Frontiers in Immunology, 9, 982.  
&lt;br&gt;https://doi.org/10.3389/fimmu.2018.00982</mixed-citation></ref><ref id="hanspub.38819-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Shin, C., Han, J.A., Koh, H., et al. (2015) CD8alpha(-) Dendritic Cells Induce Antigen-Specific T Follicular Helper Cells Generating Efficient Humoral Immune Responses. Cell Reports, 11, 1929-1940.  
&lt;br&gt;https://doi.org/10.1016/j.celrep.2015.05.042</mixed-citation></ref><ref id="hanspub.38819-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Dou, L., Ono, Y., Chen, Y.F., et al. (2018) Hepatic Dendritic Cells, the Tolerogenic Liver Environment, and Liver Disease. Seminars in Liver Disease, 38, 170-180. &lt;br&gt;https://doi.org/10.1055/s-0038-1646949</mixed-citation></ref><ref id="hanspub.38819-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">El Ansary, M., Mogawer, S., Elhamid, S.A., et al. (2013) Immunotherapy by Autologous Dendritic Cell Vaccine in Patients with Advanced HCC. Journal of Cancer Research and Clinical Oncology, 139, 39-48.  
&lt;br&gt;https://doi.org/10.1007/s00432-012-1298-8</mixed-citation></ref><ref id="hanspub.38819-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Brombacher, E.C. and Everts, B. (2020) Shaping of Dendritic Cell Function by the Metabolic Micro-Environment. Frontiers in Endocrinology (Lausanne), 11, 555. &lt;br&gt;https://doi.org/10.3389/fendo.2020.00555</mixed-citation></ref><ref id="hanspub.38819-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Dobrovolskienė, N., Pašukonienė, V., Darinskas, A., Kraśko, J.A., Žilionytė, K., Mlynska, A., et al. (2018) Tumor Lysate-Loaded Bacterial Ghosts as a Tool for Optimized Production of Therapeutic Dendritic Cell-Based Cancer Vaccines. Vaccine, 36, 4171-4180. &lt;br&gt;https://doi.org/10.1016/j.vaccine.2018.06.016</mixed-citation></ref><ref id="hanspub.38819-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Sabado, R.L., Balan, S. and Bhardwaj, N. (2017) Dendritic Cell-Based Immunotherapy. Cell Research, 27, 74-95.  
&lt;br&gt;https://doi.org/10.1038/cr.2016.157</mixed-citation></ref><ref id="hanspub.38819-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Ahmed, M.S. and Bae, Y.S. (2014) Dendritic Cell-Based Therapeutic Cancer Vaccines: Past, Present and Future. Clinical and Experimental Vaccine Research, 3, 113-116. &lt;br&gt;https://doi.org/10.7774/cevr.2014.3.2.113</mixed-citation></ref><ref id="hanspub.38819-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Chen, J.L., Lao, X.M., Lin, X.J., et al. (2016) Adjuvant Cytokine-Induced Killer Cell Therapy Improves Disease-Free and Overall Survival in Solitary and Nonmicrovascular Invasive Hepatocellular Carcinoma after Curative Resection, Medicine (Baltimore), 95, e2665. &lt;br&gt;https://doi.org/10.1097/MD.0000000000002665</mixed-citation></ref><ref id="hanspub.38819-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Durrieu, L., Lemieux, W., Dieng, M.M., et al. (2014) Implication of Different Effector Mechanisms by Cord Blood-Derived and Peripheral Blood-Derived Cytokine-Induced Killer Cells to Kill Precursor B Acute Lymphoblastic Leukemia Cell Lines. Cytotherapy, 16, 845-856. &lt;br&gt;https://doi.org/10.1016/j.jcyt.2013.12.010</mixed-citation></ref><ref id="hanspub.38819-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Chen, D., Sha, H., Hu, T., et al. (2018) Cytokine-Induced Killer Cells as a Feasible Adoptive Immunotherapy for the Treatment of Lung Cancer. Cell Death &amp; Disease, 9, Article No. 366. &lt;br&gt;https://doi.org/10.1038/s41419-018-0404-5</mixed-citation></ref><ref id="hanspub.38819-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Yu, B., Wang, J., He, C., et al. (2017) Cytokine-Induced Killer Cell Therapy for Modulating Regulatory T Cells in Patients with Non-Small Cell Lung Cancer. Experimental and Therapeutic Medicine, 14, 831-840.  
&lt;br&gt;https://doi.org/10.3892/etm.2017.4562</mixed-citation></ref><ref id="hanspub.38819-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Pan, K., Li, Y.Q., Wang, W., Xu, L., Zhang, Y.J., Zheng, H.X., et al. (2013) The Efficacy of Cytokine-Induced Killer Cell Infusion as an Adjuvant Therapy for Postoperative Hepatocellular Carcinoma Patients. Annals of Surgical Oncology, 20, 4305-4311. &lt;br&gt;https://doi.org/10.1245/s10434-013-3144-x</mixed-citation></ref><ref id="hanspub.38819-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Schmeel, L.C., Schmeel, F.C., Coch, C. and Schmidt-Wolf, I.G. (2015) Cytokine-Induced Killer (CIK) Cells in Cancer Immunotherapy: Report of the International Registry on CIK Cells (IRCC). Journal of Cancer Research and Clinical Oncology, 141, 839-849. &lt;br&gt;https://doi.org/10.1007/s00432-014-1864-3</mixed-citation></ref><ref id="hanspub.38819-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Yu, R., Yang, B., Chi, X., et al. (2017) Efficacy of Cytokine-Induced Killer Cell Infusion as an Adjuvant Immunotherapy for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Drug Design, Development and Therapy, 11, 851-864. &lt;br&gt;https://doi.org/10.2147/DDDT.S124399</mixed-citation></ref><ref id="hanspub.38819-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Lee, J.H., Lee, J.H., Lim, Y.S., Yeon, J.E., Song, T.J., Yu, S.J., Gwak, G.Y., Kim, K.M., Kim, Y.J., Lee, J.W. and Yoon, J.H. (2015) Adjuvant Immunotherapy with Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma. Gastroenterology, 148, 1383-1391.e6. &lt;br&gt;https://doi.org/10.1053/j.gastro.2015.02.055</mixed-citation></ref><ref id="hanspub.38819-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Bonanno, G., Iudicone, P., Mariotti, A., et al. (2010) Thymoglobulin, Interferon-Gamma and Interleukin-2 Efficiently Expand Cytokine-Induced Killer (CIK) Cells in Clinical-Grade Cultures. Journal of Translational Medicine, 8, Article No. 129. &lt;br&gt;https://doi.org/10.1186/1479-5876-8-129</mixed-citation></ref><ref id="hanspub.38819-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Chen. C.L., Pan, Q.Z., Weng, D.S., et al. (2018) Safety and Activity of PD-1 Blockade-Activated DC-CIK Cells in Patients with Advanced Solid Tumors. Oncoimmunology, 7, e1417721. &lt;br&gt;https://doi.org/10.1080/2162402X.2017.1417721</mixed-citation></ref><ref id="hanspub.38819-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, J., Li, H., Gao, D., et al. (2018) A Prognosis and Impact Factor Analysis of DC-CIK Celltherapy for Patients with Hepatocellular Carcinoma Undergoing Postoperative TACE. Cancer Biology &amp; Therapy, 19, 475-483.  
&lt;br&gt;https://doi.org/10.1080/15384047.2018.1433501</mixed-citation></ref><ref id="hanspub.38819-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Ma, Y.J., He, M., Han, J.A., et al. (2013) A Clinical Study of HBsAg-Activated Dendritic Cells and Cytokine-Induced Killer Cells during the Treatment for Chronic Hepatitis B. Scandinavian Journal of Immunology, 78, 387-393.  
&lt;br&gt;https://doi.org/10.1111/sji.12097</mixed-citation></ref><ref id="hanspub.38819-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Brudno, J.N. and Kochenderfer, J.N. (2018) Chimeric Antigen Receptor T-Cell Therapies for Lymphoma. Nature Reviews Clinical Oncology, 15, 31-46. &lt;br&gt;https://doi.org/10.1038/nrclinonc.2017.128</mixed-citation></ref><ref id="hanspub.38819-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">June, C.H., O’Connor, R.S., Kawalekar, O.U., Ghassemi, S. and Milone, M.C. (2018) CAR T Cell Immunotherapy for Human Cancer. Science, 359, 1361-1365. &lt;br&gt;https://doi.org/10.1126/science.aar6711</mixed-citation></ref><ref id="hanspub.38819-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Lim, W.A. and June, C.H. (2017) The Principles of Engineering Immune Cells to Treat Cancer. Cell, 168, 724-740.  
&lt;br&gt;https://doi.org/10.1016/j.cell.2017.01.016</mixed-citation></ref></ref-list></back></article>